Stay updated with breaking news from Efficacy End Points. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows...
A continued statistically significant improvement in iDFS was observed for patients with HR-positive, HER2-negative early-stage breast cancer who received ribociclib plus a nonsteroidal AI vs a nonsteroidal AI alone, according to the final iDFS analysis of the phase 3 NATALEE trial.
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival benefit remains consistent in all subgroups, including in patients with stage II tumors,...
Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023. European Society...
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease